AC Immune
ACIU
46 hedge funds and large institutions have $69M invested in AC Immune in 2026 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 4 closing their positions.
1,176% more call options, than puts
Call options by funds: $1.61M | Put options by funds: $126K
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
12% more funds holding
Funds holding: 41 → 46 (+5)
1.03% less ownership
Funds ownership: 25.67% → 24.64% (-1%)
15% less capital invested
Capital invested by funds: $80.9M → $69M (-$12M)
19% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$609K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$549K |
| 3 |
Jane Street
New York
|
+$146K |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$93.3K |
| 5 |
BlackRock
New York
|
+$68.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.2M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.14M |
| 3 |
Millennium Management
New York
|
-$437K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$288K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$181K |
ACIU Hedge Fund Activity: Q1 2026 in Review
46 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in AC Immune (ACIU) for Q1 2026, worth a combined $69M — down 15% from $80.9M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ACIU positions and 4 closed out — a net gain of 5 holders — while 13 added to existing stakes and 16 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $609K. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.2M sold.
- 46 institutional investors held AC Immune (ACIU) as of Q1 2026, up from 41 in Q4 2025.
- Funds reported $69M of AC Immune stock for Q1 2026, down 15% quarter-over-quarter.
- 9 funds opened new AC Immune positions in Q1 2026 and 4 closed out, a net change of +5 holders.
- The largest AC Immune buyer in Q1 2026 was Citadel Advisors, an estimated $609K added.
- The largest AC Immune seller in Q1 2026 was Point72 Asset Management, an estimated $1.2M sold.
Based on aggregated 13F filings for Q1 2026.